Overview

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Status:
Unknown status

Trial end date:
2020-08-01

Target enrollment:
0

Participant gender:
All

Summary

This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug (droxidopa) may improve cerebral perfusion more robustly than systemic BP, possibly by direct action within the CNS vasculature. This study is designed to determine if droxidopa improves cerebral perfusion measures in PD patients with NOH, in addition to peripheral BP measures and subjective responses.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

William Ondo, MD

Collaborator:

Lundbeck LLC

Treatments:

Droxidopa

Criteria

Inclusion Criteria:

- Idiopathic Parkinson's disease patients with orthostatic hypotension (Systolic Blood
Pressure drop of > 20 mm hg or Diastolic Blood Pressure drop of >10 mm hg measured at
some point) within a month of inclusion.

Exclusion Criteria:

- Age >85

- Concurrent use of Midodrine

- Medical conditions that in the opinion of the investigator, might not allow for same
completion of the study i.e. unstable angina, neoplasm, etc